Is the CSL share price a buy?

Is the CSL Limited (ASX:CSL) share price a buy? The giant healthcare business has just reported its FY20 result to the share market.

Is the CSL Limited (ASX: CSL) share price a buy?

CSL is the largest healthcare business on the ASX, it's actually the biggest business in the S&P/ASX 200 Index (ASX: XJO).

The company recently released its FY20 result which included a number of interesting talking points.

CSL's FY20 result

In constant currency terms, which is how CSL likes to report its result, net profit after tax (NPAT) rose by 17% to US$2.1 billion and revenue increased 9%.

CSL said this result reflected solid growth in the immunogloblin portfolio. Privigen sales grew by 20% and Hizentra sales increased by 34%. There was continued growth with high patient demand for chronic conditions.

The haemophilia portfolio has successfully evolved, driven by Idelvion with sales up by 25%.

CSL also said that the transition to its own distribution model in China has been completed. That was a drag on earnings in FY20 with albumin sales down by 36% – which was in line with guidance. This Chinese transition will improve CSL's participation in the value chain as well as allowing the company to work directly with clinicians.

The healthcare giant also said that it delivered on its product differentiation strategy with strong profit growth for Seqirus.

So far, CSL said that there has been no material revenue impact to date resulting from the COVID-19 pandemic, though the situation is "fluid and some elements are unpredictable".

The CSL final dividend was US$1.07 per share, equating to $1.48 in Australian dollar terms. That brings the full year dividend growth to 11% in AUD terms, a total of $2.95. At the current CSL share price it has a dividend yield of around 1%.

CSL announced that clinical trials were suspended in FY20 as a COVID-19 precaution, but these trials have now recommenced.

Investing for growth

I have always been impressed by CSL's commitment to research and development. It is continuing to invest in its pipeline of products and it's also involved in the global effort to tackle COVID-19 with one vaccine partnership and four therapeutic candidates under investigation and development. It's the new products that will drive future earnings. 

What I thought was interesting this year was that the company made two bolt-on acquisitions. It acquired the license rights for a haemophilia B gene therapy program, etranacogene dezparvovec which had an upfront cash payment of US$450 million with further payments for milestones and royalties. It also acquired biotech company Vitaeris which is focused on the development of a treatment for rejection in solid organ kidney transplant patients.

Despite CSL having a market capitalisation of well over $100 billion, the company has still has plenty of growth potential – it's investing for growth. Major capital projects are underway at all manufacturing sites to support future demand and in FY20 it opened 40 new plasma collection centres in the US.

Is the CSL share price a buy today?

In FY21 CSL is expecting net profit to be in the range of approximately US$2.1 billion to US$2.265 billion. That top end of guidance would be up to 8%. CSL tends to be a bit conservative with its guidance, so I wouldn't be surprised to see CSL beat the guidance in FY21.

Nonetheless, CSL is looking quite pricey. It's true that people who thought CSL was expensive at a share price of $200 have missed out on a capital gain of 50%. It's one of the few ASX blue chips that is still growing profit during COVID-19. Its investing for growth should lead to longer-term profit growth. There's a lot to like and I'd prefer to hold it for the long-term than a resource business or bank. 

But how much should we pay for a business that isn't growing that fast? CSL is now a healthcare behemoth – the next decade isn't going to be as good as the last decade.

At the current CSL share price it's trading at 39x FY22's estimated earnings. I think there are plenty of smaller businesses with much more growth potential like A2 Milk Company Ltd (ASX: A2M) which seem like they can produce better returns than CSL at the current prices.

Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Happy investor on tablet with finance graphs rising in overlay.
Growth Shares

Could these 3 ASX shares grow into $100 billion companies by 2036?

I wouldn't rule out any of these three companies reaching this milestone, although I'd be much more confident backing one…

Read more »

Two men sit side by side on a couch with video game controls in their hands and expressive looks on their faces.
Growth Shares

3 ASX growth shares almost as exciting as the GTA 6 release

It is a great time to be a gamer. But are these shares just as exciting?

Read more »

Happy young couple riding a motorbike together.
Growth Shares

3 ASX shares I think could be worth twice as much in 5 years

These shares appear well-placed for growth over the next half-decade.

Read more »

Happy businessman fist pumping while looking at a tablet.
Growth Shares

Why WiseTech and these ASX growth shares make my shortlist for 2027

There are reasons to be positive on these growing companies.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Growth Shares

Could this ASX 200 share turn $10,000 into $20,000 by 2030?

The company already has an impressive global presence, but I think there's still plenty of room to grow.

Read more »

Two shop workers smiling and looking at a laptop surrounded by plants.
Growth Shares

The ASX's next great growth stock? I've narrowed my shortlist to two

These companies have already made impressive progress, but I think there's still a lot more they could achieve.

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Growth Shares

2 ASX shares highly recommended to buy: Experts

Multiple brokers are excited about these ideas.

Read more »

A couple sits on the bed in their hotel room wearing white robes, with both having seen bad news on their phones.
Growth Shares

A rare buying opportunity in 1 of Australia's top shares?

This business is delivering significant financial growth.

Read more »